A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

BACKGROUND: This double-blind, randomized, 78-week study evaluated the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-06410293, a candidate adalimumab biosimilar, versus adalimumab reference product (Humira(®)) sourced from the EU (adalimumab-EU) in biologic-naïve pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy M., Alten, Rieke, Pileckyte, Margarita, Lobello, Kasia, Hua, Steven Y., Cronenberger, Carol, Alvarez, Daniel, Bock, Amy E., Sewell, K. Lea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094896/
https://www.ncbi.nlm.nih.gov/pubmed/30111357
http://dx.doi.org/10.1186/s13075-018-1676-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094896/
https://www.ncbi.nlm.nih.gov/pubmed/30111357
http://dx.doi.org/10.1186/s13075-018-1676-y

Ejemplares similares